Eli Lilly follows J&J in suing Biden administration over 340B rebates
Major drugmakers are filing lawsuits against the HHS and HRSA to try to resuscitate plans to issue hospitals rebates instead of giving them upfront discounts on 340B drugs.
Lilly sues US agency over blocking of drug-rebate program
Eli Lilly said on Thursday it sued the federal Health Resources and Services Administration (HRSA) over allegedly blocking the company's plan to change the way it offers drug discounts to hospitals. The case centers on the federal 340B program,
Eli Lilly, J&J Sue US Over Rejected Changes To Drug Discounting Program
Key Takeaways Eli Lilly has joined Johnson & Johnson in filing a lawsuit against the federal government over a decades-old drug discounting program.The companies have said the 340B program, which requires drugmakers to sell discounted medications to certain medical facilities,
Eli Lilly follows JNJ in suing govt. over 340B drug-discount program
Eli Lilly (NYSE:LLY) has filed a lawsuit over a U.S. health agency's alleged attempts to block its model for offering rebates for drugs supplied under the government's 340B Program, days after its rival Johnson & Johnson (NYSE:JNJ) filed a similar lawsuit.
Lilly Sues US Agency For Blocking Proposed Drug Rebate Plan
Eli Lilly sued the Health Resources and Services Administration (HRSA) for allegedly blocking the pharma giant's proposal to change the manner by which it offers discounts on medicines under the 340B program.
Eli Lilly’s tirzepatide cuts risk of worsening heart failure in HFpEF, obese patients
Tirzepatide, currently marketed by Eli Lilly (NYSE:LLY) as Mounjaro and Zepbound for diabetes and weight loss, respectively, ...
Medicaid dominates coverage of Novo, Lilly weight-loss drugs
State Medicaid programs for low-income families are the single biggest source of coverage, giving 31.6 million people access ...
GlobalData on MSN10h
Eli Lilly reports outcomes from Phase III trial of tirzepatide for HFpEF
The trial met both primary endpoints, with tirzepatide showing a 38% decrease in heart failure outcomes compared to placebo.
STAT5h
Novartis ramps up in radiopharma, and Eli Lilly adds Zepbound details
In today's biotech news, Zepbound trial data, Regenxbio's Duchenne muscular dystrophy treatment, and Intellia's promising ...
Eli Lilly and Novo Want to Shake off Ozempic Copycats. Are They Ready to Meet Demand?
But for diabetes and obesity drugs like Ozempic and Zepbound, known as GLP-1s, cheaper copycats emerged almost ...
Benzinga.com9h
Eli Lilly's Zepbound/Mounjaro Shows Cardiovascular Benefits In Patients With Obesity-Related Heart Failure
Eli Lilly's tirzepatide cut cardiovascular mortality and heart failure event risk by 38% in HFpEF patients over a ...
Eli Lilly & Co (LLY) Receives a Hold from Evercore ISI
Evercore ISI analyst Umer Raffat maintained a Hold rating on Eli Lilly & Co (LLY – Research Report) today. The company’s shares closed last ...
Yahoo1d
If You Bought 1 Share of Eli Lilly in 1984, Here's How Many Shares You Would Own Now
The stock has also performed well this year, rising roughly 36% (as of Nov. 14), ahead of the broader market. Given that ...
Should You Forget Eli Lilly and Buy This Magnificent Biotech Stock Instead?
Eli Lilly (NYSE: LLY) sells a broad range of pharmaceuticals treating various diseases, but one portfolio in particular has ...
Barclays Keeps Their Buy Rating on Eli Lilly & Co (LLY)
Barclays analyst Carter Gould maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price target of $975.00.
Eli Lilly's weight-loss drug helps nearly 99% of patients remain diabetes-free
Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...
Yahoo Finance5h
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the ...